Beyond the Lab: Can a New Rapid Ebola Test Halt the Next Pandemic?

SALT LAKE CITY, UT – June 02, 2026 – In the global battle against infectious diseases, time is the eternal enemy. For a disease as swift and brutal as Ebola, every hour lost to diagnosis is an hour ceded to the virus. This stark reality lends a sense of urgency to today's announcement from Co-Diagnostics, a Utah-based molecular diagnostics firm, detailing progress on a new rapid PCR test for Ebola designed for point-of-care use. The promise is tantalizing: a gold-standard diagnosis, not in a distant city lab days later, but in roughly 30 minutes, right on the front lines of an outbreak.

Working with its Indian joint venture, CoSara Diagnostics, the company is developing a tool that could fundamentally alter the calculus of Ebola response. As the World Health Organization grapples with a recent Ebola outbreak caused by the Bundibugyo virus—an emergency that has already claimed over 200 lives and is outpacing response operations—the gap between our current capabilities and our needs has never been clearer. Co-Diagnostics believes its technology can help close that gap. Yet, the path from a promising press release to a life-saving tool in the hands of a healthcare worker in a remote clinic is fraught with regulatory, logistical, and financial hurdles. The question is not just whether the technology works, but whether it can be deployed where it matters, when it matters.

Speed and Specificity at the Frontline

The core of the company's strategy lies in a dual-assay approach for its Co-Dx PCR Pro® platform, a portable device operated via a smartphone. The first is a 'pan-Ebola' test, a rapid screening tool designed to give a quick yes-or-no answer for the presence of any ebolavirus. This would allow for immediate isolation of suspected cases, a critical step in breaking chains of transmission.

The second, a more sophisticated multiplex assay, aims to differentiate between the specific species of the virus, including the notoriously lethal Zaire ebolavirus and the Sudan, Taï Forest, and Bundibugyo strains currently plaguing Central Africa. Knowing the specific enemy is vital for epidemiologists tracking an outbreak and for deploying targeted treatments or vaccines.

Technically, the most significant leap forward is that this will be the first blood-based pathogen test for the Co-Dx PCR platform. "Many of the world's most serious infectious diseases are identified using blood samples, and expanding the platform to support those applications would represent an important step forward for Co-Diagnostics," said CEO Dwight Egan. This move expands the platform's potential far beyond the swab-based respiratory tests it was initially developed for during the COVID-19 pandemic.

Currently, the gold standard for Ebola diagnosis is a laboratory-based RT-PCR test. While highly accurate, it's a system crippled by logistics. Samples must be carefully collected, preserved, and transported—often over difficult terrain—to a centralized lab. The turnaround can take days. In that time, a patient's condition can deteriorate, and they can infect countless others. A portable, 30-minute PCR test effectively moves the entire laboratory to the patient's bedside, a paradigm shift that public health officials have dreamed of for decades.

The Gauntlet of Regulation and Reality

For all its potential, the Co-Dx platform, including the new Ebola test, exists today only in a state of regulatory limbo. The company's press release is punctuated with the critical disclaimer: "subject to review by the FDA and/or other regulatory bodies and is not yet available for sale." This is not a minor footnote; it is the central challenge.

Co-Diagnostics has begun the arduous process, submitting its PCR Pro instrument for 510(k) clearance from the U.S. Food and Drug Administration (FDA) and applying for clearance for an over-the-counter COVID-19 test. But approval is not guaranteed, and timelines are notoriously unpredictable. This means the foundational platform upon which the Ebola test will run has not yet been greenlit in its home country, let alone for global use.

For deployment in Ebola-affected regions, the company will likely need to navigate the World Health Organization's prequalification process, a rigorous assessment of a diagnostic's quality, safety, and performance. During past crises, the WHO has used an expedited Emergency Use Assessment and Listing (EUAL) pathway. However, that fast-track for Ebola diagnostics was closed in 2016. This suggests Co-Diagnostics will face the standard, more lengthy prequalification journey, a process that ensures efficacy but dashes hopes for immediate deployment in the current outbreak.

A New Model for Global Health?

Perhaps the most forward-looking aspect of Co-Diagnostics' strategy is its infrastructure. The joint venture with CoSara in India and a more recent manufacturing venture in Saudi Arabia signal a move away from a centralized, Western-based production model. By localizing manufacturing, the company aims to create more resilient and responsive supply chains, potentially lowering costs and speeding up distribution in emerging markets.

"The progress we are making with Ebola reflects not only the flexibility of our assay design capabilities, but also the value of the international infrastructure we have built through CoSara," Egan stated, highlighting the synergy between rapid development and localized deployment.

This model directly addresses a key lesson from the COVID-19 pandemic: global health is dangerously vulnerable when manufacturing capacity for essential tools is concentrated in a few wealthy nations. By building factories closer to where diseases are likely to emerge, the company is positioning itself not just as a technology developer, but as a key player in global health security infrastructure. The plan includes partnering with non-governmental organizations (NGOs) to get these tests into the field, leveraging their existing networks and on-the-ground expertise. However, this global vision depends entirely on the technology clearing its numerous regulatory hurdles first.

The High-Stakes Gamble

The diagnostics market is not an open field. Co-Diagnostics faces established competitors like Cepheid, whose GeneXpert system is already a familiar point-of-care workhorse in many parts of the world for diseases like tuberculosis and Ebola. To succeed, the Co-Dx platform must prove it is not just as good, but better—either faster, cheaper, more accurate, or easier to use in challenging environments.

This is a high-stakes gamble for the company, which has been investing heavily in R&D not just for Ebola, but for a suite of tests including tuberculosis, HPV, and respiratory pathogens. Securing funding through recent private placements shows investor confidence, but it also underscores the constant need for capital to fuel a vision that has yet to generate significant commercial revenue from its flagship platform.

The development of a rapid Ebola test is a laudable and necessary goal. It represents the intersection of technological innovation and profound human need. But as we watch this story unfold, it serves as a powerful case study in the gap between how our world should work—where a life-saving invention is rushed to the front lines—and how it actually does, mired in a complex web of regulations, market forces, and logistical realities that a virus simply does not respect.